https://www.bioworld.com/rss en-us Missing statistical significance on the primary overall survival phase III endpoint with antibody-drug conjugate (ADC) sigvotatug vedotin compared with docetaxel in non-small-cell lung cancer (NSCLC), Pfizer Inc., which gained the candidate through its $43 billion buyout of Seagen Inc. in 2023, is forging ahead based on subgroup signals, phase I data and an ongoing phase III Keytruda combination effort currently underway. http://www.bioworld.com/articles/732060 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732060-pfizer-adc-from-seagen-m-and-a-fails-in-phase-iii-nsclc-trial Lung cancer illustration MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732152 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732152-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732123 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732123-rin-institute-discovers-new-insoluble-fibrin-targeting-adcs MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732090 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732090-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732019 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732019-sichuan-kelun-biotech-biopharmaceutical-patents-new-heterocyclic-compounds A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer. N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.]]> http://www.bioworld.com/articles/731971 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731971-hengrui-pharmaceuticals-prepares-new-adcs-for-cancer Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or antigen-binding fragments targeting V-set domain-containing T-cell activation inhibitor 1 (VTCN1, B7-H4) and tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to cytotoxic drug. They are described as potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731868 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731868-fortvita-and-innovent-patent-new-anti-trop2-b7-h4-adcs Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer. http://www.bioworld.com/articles/731865 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731865-shanghai-ruotuo-biotechnology-discovers-new-anti-egfr-her3-adcs Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results. http://www.bioworld.com/articles/731830 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731830-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer Gastric cancer If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731829 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731829-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731772 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731772-pheon-therapeutics-discovers-new-cdcp1-targeting-adcs If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731634 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass Researchers from Pfizer reported preclinical efficacy of PF-08052667, an antibody-drug conjugate (ADC) targeting integrin β6 (ITGB6), in non-muscle-invasive bladder cancer (NMIBC) models. http://www.bioworld.com/articles/731672 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731672-pfizers-integrin-6-adc-advances-intravesical-therapy-for-nmibc 3D rendering of drug linked to antibody Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam. http://www.bioworld.com/articles/731620 Thu, 04 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731620-ona-raises-866m-series-b-for-adcs-to-treat-advanced-cancers 3D dollar sign Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results. http://www.bioworld.com/articles/731617 Thu, 04 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731617-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer Gastric cancer ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77. http://www.bioworld.com/articles/731616 Thu, 04 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731616-zynlonta-lotis-position-in-dlbcl-strains-adc-shares Diffuse large B-cell lymphoma - isometric view Sotio Biotech AS’s SOT-106 has been granted orphan drug designation by the FDA for the treatment of osteosarcoma. SOT-106 is a next-generation antibody-drug conjugate targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumor-associated stroma. http://www.bioworld.com/articles/731653 Thu, 04 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731653-sotio-biotechs-sot-106-designated-orphan-drug-for-osteosarcoma Illustration of bone cancer in the knee Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology. http://www.bioworld.com/articles/731644 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731644-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal Antibodies attacking cancer cell In 2025, China’s outbound life sciences and biopharma deals reached nearly $100 billion, about 12 times the level seen in 2021, underscoring how quickly global appetite for Chinese assets has accelerated, according to a recent report by L.E.K. Consulting. http://www.bioworld.com/articles/731530 Tue, 02 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/731530-china-deals-highlight-biopharma-evolution-reports-lek China map/flag with silhouettes of business people Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology. http://www.bioworld.com/articles/731458 Fri, 29 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731458-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal Antibodies attacking cancer cell Zhize Tongkang (Guangzhou) Biotechnology Co. Ltd. has divulged new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting claudin 6 (CLDN6) linked to a camptothecin derivative potentially useful for the treatment of cancer and fibrosis. http://www.bioworld.com/articles/731503 Fri, 29 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731503-zhize-tongkang-guangzhou-biotechnology-prepares-new-anti-cldn6-adcs Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731648 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731648-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731444 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731444-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates Payoff for the November 2023 buyout of Immunogen Inc. came for Abbvie Inc. in the form of U.S. FDA clearance for the CD123-targeting antibody-drug conjugate Decnupaz (pivekimab sunirine) to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare, aggressive and quick-killing hematologic malignancy. http://www.bioworld.com/articles/731440 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731440-elzonris-this-fda-clears-abbvies-decnupaz-in-bpdcn Blood cells and destruction of cancer cell Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases. http://www.bioworld.com/articles/731487 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731487-anti-egfr-antibody-drug-conjugates-reported-in-hutchmed-patent Kunshan Xinyunda Biotechnology Co. Ltd. has patented new antibody-drug conjugates (ADCs) consisting of humanized antibodies targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) covalently linked to a payload and potentially useful for the treatment of cancer and inflammatory disorders. http://www.bioworld.com/articles/731284 Tue, 26 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731284-kunshan-xinyunda-biotechnology-synthesizes-new-adam9-targeting-adcs Concept art of an antibody-drug conjugate Iksuda Therapeutics Ltd. and UCL Business Ltd. have prepared new antibody-drug conjugates comprising antibodies targeting B7 homolog 3 (B7-H3, CD276) covalently linked to cytotoxic drug, designed for potential use in the treatment of cancer. http://www.bioworld.com/articles/731168 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731168-iksuda-and-ucl-report-new-b7-h3-targeting-adcs Antibody-drug conjugates (ADCs) with a dual payload, which deliver two distinct cytotoxic agents via a single antibody, are emerging therapeutics developed to address the limitations of classic ADCs. Primelink Biotherapeutics (Shenzhen) Co. Ltd. recently presented data for their dual-payload ADCs, highlighting PLB-015, which carries a TOP1 inhibitor and an ATR inhibitor with an anti-HER2 antibody and is designed to inhibit the DNA damage response activated by cancer cells when harmed. http://www.bioworld.com/articles/731163 Tue, 19 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731163-dual-payload-adc-holds-promise-for-treating-her2-tumors Antibody-drug conjugates floating on light purple background A recent Antelope Therapeutics SAS patent describes new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting canAg (CA242) mucin glycoepitope covalently linked to exatecan designed for use in the treatment of cancer. http://www.bioworld.com/articles/731133 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731133-antelope-therapeutics-patents-new-antibody-drug-conjugates-for-cancer CSPC Megalith Biopharmaceutical Co. Ltd. has discovered new antibody-drug conjugates (ADCs) consisting of antibodies targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drugs potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731132 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731132-cspc-megalith-biopharmaceutical-discloses-new-cdcp1-targeting-adcs